Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 8 pages
Data source: Published sources
Topics:
Ranbaxy Laboratories Limited; Global generics market; Active pharmaceutical ingredients; Ranbaxy Nigeria Limited; Abbreviated new drug application (ANDA); Novel drug delivery system (NDDS); New drug discovery research (NDDR); Controlled drug release technology; Proprietary prescription products; Product patents in India after 2005; Indian Patents Act 1970; Branded generics market; National Institute of Pharmaceutical Education and Research (India); Once-a-day cirpofloxacin; General Agreement on Tariffs and Trade (GATT)
Share a link:
https://casecent.re/p/19869
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
In 2004, Ranbaxy Laboratories Limited, India''s largest pharmaceutical company, reached the $1 billion mark in global sales - a target that it had set itself in 1993. Ranbaxy is among the top ten generics companies in the world with a strong presence in bulk drugs and branded formulations. This case highlights the growth strategies of Ranbaxy that catapulted it to a prominent position on the global pharmaceutical map, and the company''s initiative to sustain its leadership in the light of the product patents being recognised from 2005 onwards according to the World Trade Organisation regulations.
About
Abstract
In 2004, Ranbaxy Laboratories Limited, India''s largest pharmaceutical company, reached the $1 billion mark in global sales - a target that it had set itself in 1993. Ranbaxy is among the top ten generics companies in the world with a strong presence in bulk drugs and branded formulations. This case highlights the growth strategies of Ranbaxy that catapulted it to a prominent position on the global pharmaceutical map, and the company''s initiative to sustain its leadership in the light of the product patents being recognised from 2005 onwards according to the World Trade Organisation regulations.